Sangamo Therapeutics Inc (NASDAQ:SGMO) price on Thursday, March 20, fall -3.49% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.84.
A look at the stock’s price movement, the close in the last trading session was $0.87, moving within a range at $0.8244 and $0.9181. The beta value (5-Year monthly) was 1.5. Turning to its 52-week performance, $3.18 and $0.30 were the 52-week high and 52-week low respectively. Overall, SGMO moved -23.72% over the past month.
Sangamo Therapeutics Inc’s market cap currently stands at around $188.55 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-16.
The average forecast suggests up to a 1,001.87% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 68.94M, representing a 19.28% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that SGMO is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 1 recommend SGMO as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
SGMO’s current price about -12.25% and -22.27% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 37.32, while 7-day volatility ratio is 10.02% and 11.14% in the 30-day chart. Further, Sangamo Therapeutics Inc (SGMO) has a beta value of 1.47, and an average true range (ATR) of 0.11. Analysts have given the company’s stock an average 52-week price target of $2.5, forecast between a low of $2 and high of $3. Looking at the price targets, the low is -138.1% off current price level while to achieve the yearly target high, price needs to move -257.14%. Nonetheless, investors will most likely welcome a -197.62% jump to $2.5 which is the analysts’ median price.
If we refocus on Sangamo Therapeutics Inc (NASDAQ:SGMO), historical trading data shows that trading volumes averaged 5.99 over the past 10 days and 6.02 million over the past 3 months. The company’s latest data on shares outstanding shows there are 224.71 million shares.
The 4.50% of Sangamo Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 27.61% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 26.5 million on 2025-02-28, giving us a short ratio of 7.0. The data shows that as of 2025-02-28 short interest in Sangamo Therapeutics Inc (SGMO) stood at 1278.0 of shares outstanding, with shares short rising to 24.33 million registered in 2025-01-31. Current price change has pushed the stock -17.74% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SGMO stock continues to rise going into the next quarter.
